585
Views
7
CrossRef citations to date
0
Altmetric
Review

Clinical complexity of utilizing FGFR inhibitors in cancer therapeutics

, &
Pages 1413-1429 | Received 01 Jun 2020, Accepted 14 Oct 2020, Published online: 06 Nov 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Craig W. Freyer, Mitchell E. Hughes, Alison Carulli, Adam Bagg & Elizabeth Hexner. (2023) Pemigatinib for the treatment of myeloid/lymphoid neoplasms with FGFR1 rearrangement. Expert Review of Anticancer Therapy 23:4, pages 351-359.
Read now
Chen Hong, Jianping Wei, Tao Zhou, Xia Wang & Jing Cai. (2022) FGFR2-ERC1: A Subtype of FGFR2 Oncogenic Fusion Variant in Lung Adenocarcinoma and the Response to Anlotinib. OncoTargets and Therapy 15, pages 651-657.
Read now

Articles from other publishers (5)

Xinyi Zheng, Hang Wang, Junyue Deng, Minghe Yao, Xiuhe Zou, Fan Zhang & Xuelei Ma. (2023) Safety and efficacy of the pan-FGFR inhibitor erdafitinib in advanced urothelial carcinoma and other solid tumors: A systematic review and meta-analysis. Frontiers in Oncology 12.
Crossref
Ahmad Najem, Laura Soumoy, Malak Sabbah, Mohammad Krayem, Ahmad Awada, Fabrice Journe & Ghanem E. Ghanem. (2022) Understanding Molecular Mechanisms of Phenotype Switching and Crosstalk with TME to Reveal New Vulnerabilities of Melanoma. Cells 11:7, pages 1157.
Crossref
Riyad N. H. Seervai, Woo Cheal Cho, Emily Y. Chu, Mario L. Marques‐Piubelli, Debora A. Ledesma, Kristen Richards, Meghan M. Heberton, Kelly C. Nelson, Priyadharsini Nagarajan, Carlos A. Torres‐Cabala, Victor G. Prieto & Jonathan L. Curry. (2021) Diverse landscape of dermatologic toxicities from small‐molecule inhibitor cancer therapy. Journal of Cutaneous Pathology 49:1, pages 61-81.
Crossref
Kai Ran, Jun Zeng, Guoquan Wan, Xiaojie He, Zhanzhan Feng, Wang Xiang, Wei Wei, Xiang Hu, Ningyu Wang, Zhihao Liu & Luoting Yu. (2021) Design, synthesis and biological evaluations of a series of Pyrido[1,2-a]pyrimidinone derivatives as novel selective FGFR inhibitors. European Journal of Medicinal Chemistry 220, pages 113499.
Crossref
Richard J. Epstein, Li Jun Tian & Yan Fei Gu. (2021) 2b or Not 2b: How Opposing FGF Receptor Splice Variants Are Blocking Progress in Precision Oncology. Journal of Oncology 2021, pages 1-16.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.